Current Report Filing (8-k)
August 26 2019 - 8:01AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 23, 2019
PHARMACYTE
BIOTECH, INC.
(Exact Name of Registrant as Specified in
its Charter)
Nevada
|
333-68008
|
62-1772151
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
23046 Avenida de la Carlota, Suite 600
Laguna Hills, CA
|
92653
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant's telephone number, including
area code: (917) 595-2850
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[_] Written communications pursuant to Rule 425 under the Securities
Act
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act
[_] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act
[_] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the
Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company [_]
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
Item 8.01 Other Events.
Beginning August 23,
2019, PharmaCyte Biotech, Inc. (“PharmaCyte”) mailed to its stockholders a Notice of Special Meeting of Stockholders
and Proxy Statement (“Notice and Proxy Statement”) related to its Special Meeting of Stockholders (“Special Meeting”)
to be held at the Courtyard by Marriott located at 7955 Irvine Center Drive, Irvine, California 92618 on Wednesday, September 11,
2019 at 11:00 a.m. Pacific Daylight Time to consider and vote on the following matters:
|
1.
|
To approve a Certificate of Amendment to PharmaCyte’s Articles of Incorporation, as amended,
to provide PharmaCyte’s Board of Directors (“Board”) the power to designate the rights and preferences of PharmaCyte’s
preferred stock;
|
|
2.
|
To elect six directors as nominated by the Board, each to serve a one-year term;
|
|
3.
|
To ratify the appointment of Armanino LLP as PharmaCyte’s independent registered public accounting
firm for the fiscal year ending April 30, 2020; and
|
|
4.
|
To consider and act upon any other business as may properly come before the Special Meeting or
any adjournments thereof.
|
A copy of the Notice
and Proxy Statement is are attached to this Current Report on Form 8-K as Exhibits 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: August 26, 2019
|
PHARMACYTE BIOTECH, INC.
|
|
|
|
By:
|
/s/ Kenneth L. Waggoner
|
|
|
Kenneth L. Waggoner
Chief Executive Officer, President and General Counsel
|